Q2 Momentum Lifts BMY Outlook, Validating Eliquis Bridge Thesis

What happened

BMY's Q2 2026 earnings call underscored robust growth portfolio traction, with newer medicines driving results and prompting management to raise its full-year outlook. The update suggests that key risks flagged in prior reports—Eliquis volume offsetting IRA price resets and gross margin holding near 69-70%—are progressing within the guided range. This alleviates immediate concern over a margin-led de-rating and validates the bridge-year thesis that underpinned the prior WAIT rating. While Revlimid erosion likely continued its post-January 2026 acceleration, the Growth Portfolio's double-digit expansion appears sufficient to offset it and support the raised guidance. Overall, the quarter provides the observable proof points investors were awaiting, shifting the narrative from policy-fragile transition to execution-driven momentum.

Implication

Investors should view the Q2 results as a pivotal de-risking event; with raised guidance, the margin of safety on the dividend and debt service improves. The next catalysts—Librexia trial readouts in 2H2026 and sustained Opdivo Qvantig adoption—could further unlock value. However, discipline is required: monitor gross-to-net trends in Eliquis and Revlimid acceleration to ensure 'raised guidance' isn't achieved through accounting adjustments. The stock's re-rating to the base case $65 scenario is now more probable, making it appropriate to increase allocation while keeping a close eye on the 90-day operating metrics. Finally, if H2 pipeline readouts are positive, the bull case scenario gains credibility.

Thesis delta

The Q2 print confirms that Eliquis growth and gross margin are tracking management's 2026 bridge targets, shifting the prior WAIT stance to a more constructive outlook. With the primary verification checkpoints met, the investment case transitions from 'wait for confirmation' to 'accumulate on weakness,' as the policy-fragility risk has been visibly managed.